Over the past decade, a large number of studies reported a prominent role of inflammation
and immune response in atherosclerosis. Thus, therapeutic strategies to reduce
inflammation could exert beneficial effects in the prevention of atherosclerosis progression.
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) have demonstrated
their capacity to greatly reduce coronary morbidity and mortality in both primary and
secondary intervention trials. Furthermore, originally described as the most efficient drugs to …